PFE vs MRK
PFE and MRK side by side — valuation & fundamentals (public data).
Key statistics
| Metric | PFEPfizer Inc. | MRKMerck & Co., Inc. |
|---|---|---|
| Market cap | $142.77B | $314.85B |
| P/E (TTM) | 19.1 | 35.9 |
| P/B | 1.58 | 6.86 |
| P/S | 2.3x | 4.8x |
| Dividend yield | 6.84% | 2.60% |
| Revenue | $63.31B(TTM) | $65.77B(TTM) |
| Revenue growth (YoY) | -1.6% | 1.3% |
| Net income | $7.49B(TTM) | $8.94B(TTM) |
| Earnings growth (YoY) | -3.2% | 6.6% |
| EPS, diluted | $1.31(TTM) | $3.55(TTM) |
| EBIT margin | 16.3% | 34.2% |
| ROE | 8.6% | 39.8% |
| ROIC | 6.7% | 21.5% |
| 1y total return | +8.8% | +60.4% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: PFE frente a MRK
| Métrica | PFE | MRK |
|---|---|---|
| Valor final | $13.4K | $33.3K |
| Retorno total | +33.5% | +233.2% |
| CAGR | +2.8% | +12.3% |
| Volatilidad | 23.9% | 22.8% |
| Sharpe | 0.08 | 0.46 |
| Sortino | 0.11 | 0.66 |
| Caída máxima | -59.0% | -43.4% |
Basado en 2600 días de negociación comunes, 2016-03-15 → 2026-07-17 · tasa libre de riesgo 3.85% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)